SLN – silence therapeutics plc - american depository share (US:NASDAQ)

News

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Bitterroot Bio kickstarts Phase I trial for cardiovascular disease candidate [Yahoo! Finance]
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors [Yahoo! Finance]
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $45.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com